Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A.; Arance, Ana; Dutriaux, Caroline; Di Giacomo, Anna Maria; Rutkowski, Piotr; Del Vecchio, Michele; Gutzmer, Ralf; Mandala, Mario; Thomas, Luc; Demidov, Lev; Garbe, Claus; Hogg, David; Liszkay, Gabriella; Queirolo, Paola; Wasserman, Ernesto; Ford, James; Weill, Marine; Sirulnik, L. Andres; Jehl, Valentine; Bozon, Viviana; Long, Georgina V.; Flaherty, Keith

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Autor(en):

Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A.; Arance, Ana; Dutriaux, Caroline; Di Giacomo, Anna Maria; Rutkowski, Piotr; Del Vecchio, Michele; Gutzmer, Ralf; Mandala, Mario; Thomas, Luc; Demidov, Lev; Garbe, Claus; Hogg, David; Liszkay, Gabriella; Queirolo, Paola; Wasserman, Ernesto; Ford, James; Weill, Marine; Sirulnik, L. Andres; Jehl, Valentine; Bozon, Viviana; Long, Georgina V.; Flaherty, Keith

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

Lancet Oncology (2017), Bd. 18, H. 4, S. 435-445

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(17)30180-8

ISSN:

1474-5488